DENIS M. MCCARTHY, M.D., M. SC.
Physicians in the United States are now getting their first experience with ranitidine HCL (Zantac; Glaxo Inc., Fort Lauderdale, Florida), a new H2-receptor blocking antihistamine that inhibits gastric acid secretion with a potency four- to eightfold that of cimetidine (1, 2). In June, the FDA approved marketing of the drug for short-term oral use in the treatment of duodenal ulcer and for unrestricted use in hypersecretory states, such as the Zollinger-Ellison syndrome. The drug is not yet approved for gastric ulcer, maintenance therapy in duodenal ulcers, or parenteral use. Ranitidine received a therapeutic rating of 1C, which the FDA assigns
Learn more about subscription options.
Register Now for a free account.
MCCARTHY DM. Ranitidine or Cimetidine. Ann Intern Med. 1983;99:551–553. doi: 10.7326/0003-4819-99-4-551
Download citation file:
Published: Ann Intern Med. 1983;99(4):551-553.
Results provided by:
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use
This PDF is available to Subscribers Only